trial · primary record
Placebo
Cutaneous Lupus Erythematosus (CLE)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 140 |
| Primary completion | 2029-08 |
| Primary endpoint | Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 24 |
| Registry ID | NCT07900867 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:49.178Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07900867
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Placebo · compound